Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
SII.TO 3.52IPCO.TO -0.15DC.A.TO 0.3NESN-SIX 0MCK 13.94GOOG -1.34XLV 0.79TEVA 0.65
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

28.06
+0.09 (0.32%)
as of Aug 25, 2026, 2:11:02 pm Market Open.
582 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 25, 2026, 12:00 am

This summary was created by AI, based on 24 opinions in the last 12 months.

Pfizer Inc. (PFE) is facing significant challenges as it navigates a patent cliff following the success of its COVID-19 vaccine. Many experts are concerned about its ability to generate new blockbuster drugs and the sustainability of its high dividend yields, which currently range from 6.4% to 7%. Several reviews emphasize that while the dividend is attractive, the company lacks earnings momentum and has uncertainty surrounding its drug pipeline. The stock trades at low earnings multiples, suggesting it may be undervalued, but experts warn that the lack of growth drivers could limit upside potential. Overall, patience may be required for investors looking for signs of recovery or growth in the company's future, especially as its recent acquisitions are yet to yield significant results.

consensus icon
Consensus
Neutral
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
COMMENT

Pfizer Inc(PFE)

Apr 29, 2022
They report Tuesday. They've made a lot of money during the pandemic. He hopes they buy another drug company to make up for looming patent explorations in the coming years. Shares were crushed today. Good yield and trades at 6x earnings, though.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$49.07

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Pfizer Inc(PFE)

Apr 19, 2022
Stockchase Research Editor: Michael O'Reilly PFE has a long pipeline of new drugs focusing on oncology, rare diseases and vaccines, generating over $50 billion in annual sales. It trades at 13x earnings compared to peers at 20x. Latest reported earnings beat expectations by 27% and supports a ROE over 34%. Its dividend is backed by a payout ratio under 40% of cashflow. It is managing its cash reserves conservatively, maintaining a good war chest, while still retiring debt. We would recommend a stop loss at $42.00, looking to achieve $60.50 -- upside potential of 19%. Yield 3.0% (Analysts’ price target is $60.47)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$49.58

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 07, 2022
Has done extremely well with Covid solutions. Not inexpensive for its growth rate. A concern for the stock, though not for humanity, is this opportunity will exhaust itself. Not a bad name if Covid will be a chronic situation. All pharma races the patent clock. He'd prefer MRK.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$54.52

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Mar 31, 2022
Value and price momentum score well. High ROE, 13x price to earnings. Healthy yield of 3%, very reasonable payout ratio. You can own it through the cycles.
Photo of Jason MannJason Mann
Owned
Unlock Rating
$52.37

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

Feb 24, 2022
(A Top Pick Sep 24/20, Up 28.9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE has triggered its stop at $46. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 23%, when combined with the previous recommendation to cover half.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$45.59

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 24, 2022
Suffered recently a bit, as shine from Covid has worn off. Great defensive growth name. Likes healthcare in general. Don't sell it to buy LLY, but nothing against LLY. Trades at 6x forward earnings. Great cardio drug that could be a gamechanger, strong pipeline. Yield is 3.5%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$45.59

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 18, 2022
Has recently sold shares in company. Long term, pandemics will remain a fact of life. Has good pipeline of new drugs being developed.
Photo of Jamie Murray Jamie Murray
No
Unlock Rating
$48.53

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Feb 03, 2022
R&D has become much more concentrated. Cashflow windfall being used to expand pipeline. CEO has done exceptional job navigating the vaccine environment. Tuck-in acquisitions. Executing well, deserves the multiple bump. Yield is 3%. (Analysts’ price target is $58.53)
Photo of Paul MacDonaldPaul MacDonald
Owned
Unlock Rating
$53.30

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

Jan 20, 2022
(A Top Pick Sep 24/20, Up 51.5%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend tailing up the stop (from $42) to $46.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$54.05

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 12, 2022
One of the world's largest biopharma companies. Expected revenue of 97B USD this year. Likes it because of its rapidly improving pipeline, especially the cardio drug. Vaccine will produce cashflow windfalls over the near term, plus lots of runway. Continuing shots needed, anti-viral pill will be in high demand. Good valuation. Yield is 2.86%, expected to grow. (Analysts’ price target is $56.61)
Photo of Stan WongStan Wong
Owned
Unlock Rating
$56.59

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 06, 2022
Leadership position in vaccine fight. If you invest here, and pandemic goes away, PFE's fortunes could regress to the mean. It won't have the wind at its back anymore. The uncertainty makes him pass.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$55.34

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 08, 2021
He stays away from drug companies, always forced to do acquisitions. Costly and competitive business. Pressures from government. Boost from pandemic, and this will continue. Reasonable valuation. He prefers medical devices, where you don't need a PhD to understand what's coming next. Attractive yield about 3%.
Photo of John O'Connell, CFAJohn O'Connell, CFA
No
Unlock Rating
$51.31

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 03, 2021
Among the vaccine stocks, he feels safe with this. They're coming out with their Covid pill treatment.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$54.27

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Nov 22, 2021
Don't sell. Incredibly low valuation. Well positioned, well diversified. Established distribution network. Great long-term growth story over time.
Photo of John ZechnerJohn ZechnerUnlock Rating
$51.34

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Oct 29, 2021
They face a patent cliff in 2022, so will the Covid booster cover this? They report Tuesday.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$43.74

Stock price when the opinion was issued

$28.45

As of Aug 25, 2026. Market Open.

biotechnologypharmaceutical
Showing 151 to 165 of 887 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

NTR.TO -1.87$101
TFPM 0$
OGC.TO -0.31$42.91
SLB -0.3$53.7
ARG.TO 0.39$8.61
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

SII.TO 3.52$190.71
IPCO.TO -0.15$35.07
DC.A.TO 0.3$5.45
NESN-SIX 0$
MCK 13.94$887.73

Popular Articles

Latest Sell Signals

RKLB -1.15$67.13
INTC 0.47$87.73
MSFT 2.5$489.81
WSP.TO -2.54$189.74
CLS.TO 7.17$414.53

Most Recent Experts

Rick Rule

Rick Rule

Rule Investment Media

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like